Alain is a medical oncologist and a renowned expert in the entry-into-man phase of oncology drug development. He has broad pharma experience in supervising clinical programs from the preclinical/translational stage to IPO at the director, VP, and CMO levels in the US and EU (Roche, Janssen, Regeneron, arGEN-X).
His area of expertise also includes chemotherapy, small molecule targeted therapy and biologics (monoclonal antibodies).
Most recently, he focused on immuno-oncology development targeting co-stimulatory receptors and modification of the tumor micro-environment.
His regulatory experience ranges from IND/IMPD-CTA write-up to IND/BLA submission and approval.
Alain also has senior corporate-level experience with board presentations/communications and fund-raising.